Nifty
Sensex
:
:
14238.90
48347.59
-133.00 (-0.93%)
-530.95 (-1.09%)

Pharmaceuticals & Drugs - Global

Rating :
61/99

BSE: 532321 | NSE: CADILAHC

467.40
25-Jan-2021
  • Open
  • High
  • Low
  • Previous Close
  •  465.35
  •  473.65
  •  455.50
  •  460.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3542288
  •  16536.67
  •  509.20
  •  202.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 47,793.42
  • 28.26
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 54,884.13
  • 0.75%
  • 4.07

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.88%
  • 0.92%
  • 5.78%
  • FII
  • DII
  • Others
  • 5.24%
  • 11.41%
  • 1.77%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.90
  • 8.62
  • 6.04

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.59
  • 3.60
  • -0.34

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.91
  • -9.50
  • -12.49

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.52
  • 24.77
  • 20.51

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.43
  • 4.73
  • 3.57

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.94
  • 16.10
  • 13.38

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
3,820.00
3,366.60
13.47%
3,639.90
3,496.30
4.11%
3,752.10
3,732.80
0.52%
3,638.10
3,577.90
1.68%
Expenses
2,956.60
2,731.00
8.26%
2,824.50
2,837.60
-0.46%
2,960.90
2,922.00
1.33%
2,944.90
2,738.00
7.56%
EBITDA
863.40
635.60
35.84%
815.40
658.70
23.79%
791.20
810.80
-2.42%
693.20
839.90
-17.47%
EBIDTM
22.60%
18.88%
22.40%
18.84%
14.01%
14.01%
19.05%
23.47%
Other Income
27.50
26.90
2.23%
22.50
22.60
-0.44%
44.30
38.40
15.36%
20.10
31.00
-35.16%
Interest
45.70
89.70
-49.05%
67.70
89.10
-24.02%
82.50
77.30
6.73%
80.50
45.50
76.92%
Depreciation
179.00
172.30
3.89%
176.80
171.60
3.03%
178.50
155.60
14.72%
174.10
153.70
13.27%
PBT
534.20
122.40
336.44%
593.40
393.90
50.65%
522.00
605.90
-13.85%
457.10
671.70
-31.95%
Tax
110.60
39.50
180.00%
123.50
79.10
56.13%
108.50
126.70
-14.36%
92.70
158.60
-41.55%
PAT
423.60
82.90
410.98%
469.90
314.80
49.27%
413.50
479.20
-13.71%
364.40
513.10
-28.98%
PATM
11.09%
2.46%
12.91%
9.00%
7.11%
7.11%
10.02%
14.34%
EPS
4.62
1.05
340.00%
4.43
2.96
49.66%
28.29
28.29
0.00%
3.65
4.99
-26.85%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
14,850.10
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
5,263.30
4,630.60
Net Sales Growth
4.77%
8.26%
10.13%
27.49%
-0.53%
8.96%
19.76%
13.63%
20.79%
13.66%
 
Cost Of Goods Sold
8,461.60
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
1,464.10
1,286.20
Gross Profit
6,388.50
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
3,799.20
3,344.40
GP Margin
43.02%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
66.60%
67.96%
72.18%
72.22%
Total Expenditure
11,686.90
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
4,181.50
3,614.10
Power & Fuel Cost
-
268.80
247.20
226.30
174.50
168.80
145.40
129.70
124.40
93.40
78.90
% Of Sales
-
1.89%
1.88%
1.89%
1.86%
1.79%
1.68%
1.80%
1.96%
1.77%
1.70%
Employee Cost
-
2,389.80
2,099.40
1,825.20
1,485.20
1,261.60
1,096.50
974.00
818.40
679.90
584.00
% Of Sales
-
16.77%
15.95%
15.27%
15.84%
13.38%
12.67%
13.48%
12.87%
12.92%
12.61%
Manufacturing Exp.
-
1,468.00
1,334.70
1,211.40
955.30
1,019.60
1,136.90
936.50
897.30
718.90
553.40
% Of Sales
-
10.30%
10.14%
10.13%
10.19%
10.82%
13.14%
12.96%
14.11%
13.66%
11.95%
General & Admin Exp.
-
909.20
701.50
504.60
466.00
432.70
326.80
365.70
342.20
271.90
234.90
% Of Sales
-
6.38%
5.33%
4.22%
4.97%
4.59%
3.78%
5.06%
5.38%
5.17%
5.07%
Selling & Distn. Exp.
-
1,209.50
914.60
1,014.50
826.40
979.60
960.30
902.40
857.50
767.40
710.70
% Of Sales
-
8.49%
6.95%
8.49%
8.81%
10.39%
11.10%
12.49%
13.49%
14.58%
15.35%
Miscellaneous Exp.
-
984.30
748.50
687.00
502.60
561.80
417.40
310.30
157.40
185.90
710.70
% Of Sales
-
6.91%
5.69%
5.75%
5.36%
5.96%
4.82%
4.30%
2.48%
3.53%
3.58%
EBITDA
3,163.20
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
1,081.80
1,016.50
EBITDA Margin
21.30%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
16.51%
17.67%
20.55%
21.95%
Other Income
114.40
117.10
208.50
113.30
147.10
116.60
57.20
58.00
38.40
53.00
22.80
Interest
276.40
341.80
195.80
91.10
63.10
52.80
67.90
90.20
168.70
182.70
69.90
Depreciation
708.40
696.50
598.60
538.80
373.30
292.10
287.30
201.20
184.70
157.90
126.90
PBT
2,106.70
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
794.20
842.50
Tax
435.30
319.80
530.30
564.40
128.90
177.40
259.40
106.00
118.80
113.00
106.40
Tax Rate
20.66%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
14.23%
12.63%
PAT
1,671.40
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
652.60
711.00
PAT before Minority Interest
1,679.70
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
681.20
736.10
Minority Interest
8.30
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
-28.60
-25.10
PAT Margin
11.26%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
11.12%
10.28%
12.40%
15.35%
PAT Growth
20.24%
-36.30%
5.19%
17.82%
-23.11%
64.64%
42.92%
22.97%
0.14%
-8.21%
 
EPS
16.33
11.21
17.60
16.73
14.20
18.47
11.22
7.85
6.38
6.37
6.95

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
2,585.90
2,171.50
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
2,483.50
2,069.10
Non-Current Liabilities
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
1,555.10
956.30
Secured Loans
1,953.60
2,332.80
200.60
319.60
393.80
664.00
851.40
917.20
901.90
670.90
Unsecured Loans
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
510.80
508.80
420.40
92.00
Long Term Provisions
235.20
184.10
155.90
151.20
120.70
90.40
76.10
66.50
75.60
61.90
Current Liabilities
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
2,191.60
1,415.90
Trade Payables
2,031.00
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
545.50
570.60
Other Current Liabilities
2,139.60
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
509.20
730.90
367.30
Short Term Borrowings
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
687.10
259.80
Short Term Provisions
272.30
189.40
152.20
68.90
81.30
382.50
292.70
247.30
228.10
218.20
Total Liabilities
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
Net Block
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
2,857.10
1,832.60
Gross Block
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
3,990.90
2,801.70
Accumulated Depreciation
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
1,096.00
929.90
Non Current Assets
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
3,610.00
2,485.30
Capital Work in Progress
741.50
837.20
1,527.20
1,543.30
950.80
797.90
891.50
735.60
483.90
431.00
Non Current Investment
552.20
443.60
470.90
385.70
217.10
33.20
22.20
21.20
21.20
20.70
Long Term Loans & Adv.
332.00
410.40
300.00
384.70
661.20
637.10
511.10
400.10
247.80
201.00
Other Non Current Assets
262.10
159.80
130.30
234.10
174.70
0.00
0.00
0.00
0.00
0.00
Current Assets
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
2,813.00
2,125.30
Current Investments
212.80
229.90
274.80
49.10
199.10
121.20
64.40
93.30
3.00
0.00
Inventories
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
1,090.50
811.90
Sundry Debtors
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
920.90
765.20
Cash & Bank
964.90
548.90
1,314.90
1,543.50
638.70
669.90
548.80
583.80
466.60
295.20
Other Current Assets
1,085.50
496.00
520.70
80.00
358.90
311.50
323.50
345.90
332.00
253.00
Short Term Loans & Adv.
643.90
584.50
527.70
268.50
234.80
240.80
254.90
279.00
274.60
206.20
Net Current Assets
446.00
1,155.60
2,146.70
716.50
819.40
941.60
623.90
521.30
621.40
709.40
Total Assets
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
2,505.40
1,281.90
919.30
1,311.70
1,893.50
993.60
902.80
603.40
511.10
682.60
PBT
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
794.20
842.50
Adjustment
1,182.70
539.10
624.30
333.70
249.80
344.50
269.00
315.90
320.90
208.40
Changes in Working Capital
129.40
-971.70
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
-421.70
-175.30
Cash after chg. in Working capital
2,807.50
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
693.40
875.60
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
-172.80
-272.00
-143.50
-152.50
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.40
7.80
-30.80
14.90
-80.70
-32.50
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
-1,199.50
-466.00
Net Fixed Assets
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
-361.70
-266.60
Net Investments
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
-513.40
-99.90
Others
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
79.30
32.30
-324.40
-99.50
Cash from Financing Activity
-1,094.20
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
859.80
-172.10
Net Cash Inflow / Outflow
398.90
-1,072.20
-2.90
755.60
95.20
177.80
-63.90
206.90
171.40
44.50
Opening Cash & Equivalents
778.80
1,589.70
1,592.60
837.00
737.90
612.60
676.50
469.60
295.20
250.70
Closing Cash & Equivalent
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40
612.60
676.50
466.60
295.20

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
101.33
101.43
85.40
67.97
55.66
41.52
33.58
28.75
25.25
21.21
ROA
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
12.35%
17.62%
ROE
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
28.64%
38.85%
ROCE
10.02%
15.89%
18.26%
16.50%
28.60%
23.21%
17.20%
18.21%
24.01%
30.56%
Fixed Asset Turnover
0.88
1.05
1.38
1.38
1.76
1.80
1.63
1.55
1.58
1.75
Receivable days
97.49
99.21
83.37
76.72
63.29
56.38
51.71
52.78
57.47
47.97
Inventory Days
70.13
70.33
63.69
59.88
54.52
60.13
63.89
64.82
64.85
60.83
Payable days
68.68
72.33
71.11
74.18
67.53
55.78
50.51
43.54
49.87
64.40
Cash Conversion Cycle
98.94
97.21
75.95
62.42
50.28
60.73
65.09
74.05
72.45
44.40
Total Debt/Equity
0.77
0.76
0.62
0.75
0.43
0.62
0.79
0.99
0.89
0.50
Interest Cover
5.38
13.17
26.38
26.55
40.75
22.29
11.45
5.79
5.35
13.05

News Update:


  • Zydus Cadila gets positive results from phase 2(b) studies of COVID-19 drug Desidustat in Mexico
    25th Jan 2021, 12:13 PM

    In June 2020, Zydus Cadila had received approval from Mexico's regulatory authority Cofepris to test one of its lead research candidates Desidustat in the management of COVID-19

    Read More
  • Zydus Cadila gets final approval from USFDA for Liothyronine Sodium Tablets
    23rd Jan 2021, 11:18 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus Cadila gets DCGI’s nod to start Phase III Clinical Trial of ZyCoV-D- fully indigenously developed vaccine
    4th Jan 2021, 08:53 AM

    The company will now be initiating Phase III clinical trial in around 30,000 volunteers

    Read More
  • Zydus Cadila gets DCGI’s nod for Saroglitazar Mg for treatment of Non-Alcoholic Fatty Liver Disease in India
    30th Dec 2020, 10:31 AM

    The prevalence of NAFLD in India is estimated to be nearly 25-30% of the general population

    Read More
  • Zydus Cadila submits Phase I/II clinical trial data of ZyCoV-D
    26th Dec 2020, 09:27 AM

    The company is now planning to initiate Phase III clinical trial in around 30,000 volunteers upon receiving necessary approvals

    Read More
  • Zydus Cadila granted Fast Track Designation by the USFDA for Saroglitazar
    9th Dec 2020, 15:03 PM

    Fast Track is a process of the USFDA which expedites the review of drugs to treat serious conditions and fill an unmet medical need

    Read More
  • Zydus Cadila receives permission to initiate Phase 1 clinical trial of ZYIL1
    7th Dec 2020, 11:53 AM

    ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate

    Read More
  • Zydus Cadila gets approval from DCGI to start Phase 3 clinical trial in COVID-19 patients
    4th Dec 2020, 11:33 AM

    The trials which will commence in December will be conducted on 250 patients across 20-25 centres in India

    Read More
  • Zydus Cadila successfully completes phase 2 clinical trial in COVID-19 patients
    12th Nov 2020, 10:46 AM

    A single dose therapy will improve compliance and also make it highly affordable for patients

    Read More
  • Zydus files IND application of ZYIL1
    3rd Nov 2020, 12:28 PM

    NLPR3 inflammasomes are involved in the inflammation process by production and release of pro-inflammatory cytokines IL-1ß and IL-18

    Read More
  • Cadila Healthcare - Quarterly Results
    2nd Nov 2020, 16:21 PM

    Read More
  • Zydus to present PBC, NASH clinical trial data of Saroglitazar Mg
    2nd Nov 2020, 14:34 PM

    Saroglitazar Mg is in various stages of clinical trials to evaluate the safety, tolerability, and efficacy in patients

    Read More
  • Zydus Cadila gets tentative approval from USFDA for Dapagliflozin Tablets
    29th Oct 2020, 13:07 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus Cadila gets tentative approval from USFDA for Linagliptin Tablets
    29th Oct 2020, 12:16 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus Cadila gets final approval from USFDA to market Albuterol Tablets
    23rd Oct 2020, 11:53 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus Cadila gets approval from USFDA to market Solifenacin Succinate Tablets
    20th Oct 2020, 10:45 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus Cadila gets tentative approval from USFDA to market Tofacitinib Extended-Release Tablets
    19th Oct 2020, 11:19 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.